Clinical trial
Study of Cobimetinib in Participants With Solid Tumors
NCT00467779 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00467779 |
|---|---|
| Title | Study of Cobimetinib in Participants With Solid Tumors |
| Official title | A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Solid Tumor |
| Intervention type | Drug |
| Interventions | cobimetinib, dextromethorphan, midazolam |
| Enrollment | 119 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2014 |
| Completion | Apr 1, 2014 |
| First posted | May 1, 2007 |
| Last update posted | Aug 26, 2016 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: